These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 17995524

  • 1. Effects of therapeutic agents on the inflammatory and fibrogenic factors in IgA nephropathy.
    Ihm CG, Jeong KW, Lee SH, Lee TW, Park JK.
    Nephrology (Carlton); 2007 Dec; 12 Suppl 3():S25-6. PubMed ID: 17995524
    [Abstract] [Full Text] [Related]

  • 2. Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy.
    Xiao J, Leung JC, Chan LY, Tang SC, Lai KN.
    Clin Immunol; 2009 Aug; 132(2):266-76. PubMed ID: 19443277
    [Abstract] [Full Text] [Related]

  • 3. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy.
    Xiao J, Leung JC, Chan LY, Guo H, Lai KN.
    Nephrol Dial Transplant; 2009 Jul; 24(7):2067-77. PubMed ID: 19155534
    [Abstract] [Full Text] [Related]

  • 4. Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy.
    Leung JC, Chan LY, Tsang AW, Liu EW, Lam MF, Tang SC, Lai KN.
    Nephrol Dial Transplant; 2004 Aug; 19(8):1976-85. PubMed ID: 15187193
    [Abstract] [Full Text] [Related]

  • 5. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 6. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy.
    Moura IC, Arcos-Fajardo M, Gdoura A, Leroy V, Sadaka C, Mahlaoui N, Lepelletier Y, Vrtovsnik F, Haddad E, Benhamou M, Monteiro RC.
    J Am Soc Nephrol; 2005 Sep; 16(9):2667-76. PubMed ID: 15987753
    [Abstract] [Full Text] [Related]

  • 7. Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy.
    Lai KN, Chan LY, Guo H, Tang SC, Leung JC.
    Pediatr Nephrol; 2011 Feb; 26(2):257-66. PubMed ID: 21125406
    [Abstract] [Full Text] [Related]

  • 8. The study of Chinese medicinal herbal formula Shen San Fang in the treatment of experimental IgA nephropathy.
    Zhong Q, Leung JC, Chan LY, Tsang AW, Chen X, Lai KN.
    Am J Chin Med; 2005 Feb; 33(4):613-26. PubMed ID: 16173535
    [Abstract] [Full Text] [Related]

  • 9. [The role of steroids in the treatment of IgA nephropathy].
    Coppo R, Pozzi C, Amore A.
    G Ital Nefrol; 2009 Feb; 26(4):421-41. PubMed ID: 19644832
    [Abstract] [Full Text] [Related]

  • 10. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Monoamine oxidase inhibitors for IgA nephropathy.
    Altschuler EL.
    Med Hypotheses; 2001 Feb; 56(2):225-6. PubMed ID: 11425292
    [Abstract] [Full Text] [Related]

  • 13. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors.
    Locatelli F, Vecchio LD, Pozzi C.
    Nat Clin Pract Nephrol; 2006 Jan; 2(1):24-31. PubMed ID: 16932386
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Novel mechanisms of tubulointerstitial injury in IgA nephropathy: a new therapeutic paradigm in the prevention of progressive renal failure.
    Chan LY, Leung JC, Lai KN.
    Clin Exp Nephrol; 2004 Dec; 8(4):297-303. PubMed ID: 15619027
    [Abstract] [Full Text] [Related]

  • 16. Serological and genetic factors in early recurrence of IgA nephropathy after renal transplantation.
    Coppo R, Amore A, Chiesa M, Lombardo F, Cirina P, Andrulli S, Passerini P, Conti G, Peruzzi L, Giraudi R, Messina M, Segoloni G, Ponticelli C.
    Clin Transplant; 2007 Dec; 21(6):728-37. PubMed ID: 17988266
    [Abstract] [Full Text] [Related]

  • 17. Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy.
    Goto T, Bandoh N, Yoshizaki T, Nozawa H, Takahara M, Ueda S, Hayashi T, Harabuchi Y.
    Clin Immunol; 2008 Mar; 126(3):260-9. PubMed ID: 18249037
    [Abstract] [Full Text] [Related]

  • 18. Rapamycin slows IgA nephropathy progression in the rat.
    Tian J, Wang Y, Zhou X, Li Y, Wang C, Li J, Li R.
    Am J Nephrol; 2014 Mar; 39(3):218-29. PubMed ID: 24603476
    [Abstract] [Full Text] [Related]

  • 19. Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming growth factor-beta1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells.
    Song CY, Kim BC, Lee HS.
    Transl Res; 2008 Jan; 151(1):27-35. PubMed ID: 18061125
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.